Indication
KMT2A Rearrangement
1 clinical trial
1 product
Clinical trial
An Open Label Phase I Study of Ziftomenib as Maintenance Therapy Following Allogeneic Hematopoietic Cell TransplantationStatus: Not yet recruiting, Estimated PCD: 2026-09-01
Product
Ziftomenib